Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) FCF Margin (2021 - 2025)

Historic FCF Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to 289.72%.

  • InMed Pharmaceuticals' FCF Margin fell 646500.0% to 289.72% in Q4 2025 from the same period last year, while for Dec 2025 it was 164.69%, marking a year-over-year decrease of 137700.0%. This contributed to the annual value of 157.14% for FY2025, which is 50000.0% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its FCF Margin stood at 289.72% for Q4 2025, which was down 646500.0% from 143.52% recorded in Q3 2025.
  • InMed Pharmaceuticals' FCF Margin's 5-year high stood at 29.85% during Q2 2023, with a 5-year trough of 1728.88% in Q1 2022.
  • In the last 5 years, InMed Pharmaceuticals' FCF Margin had a median value of 164.96% in 2024 and averaged 408.46%.
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 15686500bps in 2023, then tumbled by -760500bps in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' FCF Margin stood at 1252.16% in 2021, then soared by 54bps to 577.52% in 2022, then surged by 74bps to 149.02% in 2023, then plummeted by -51bps to 225.07% in 2024, then decreased by -29bps to 289.72% in 2025.
  • Its last three reported values are 289.72% in Q4 2025, 143.52% for Q3 2025, and 136.31% during Q2 2025.